TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: E-health Resilience Program For Chronic Spine Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient of the UM Back \& Pain Center~* Primary diagnosis of neck or back pain (spine pain)~* Age 18-70~* English speaking~* Able to provide consent~* Willing to download the mobile application and comply with study procedures~* Antidepressant medications stable for ≥ 4 weeks~* No plan to initiate a new non-pharmacological pain intervention during the 30-day study period (e.g. back surgery, physical therapy, behavioral therapy~Exclusion Criteria~* Having known psychotic disorder or the presence of another psychiatric condition (e.g. severe depression \[HADS scores ≥ 15\], suicidal ideation) or cognitive impairment (e.g. severe dyslexia, TBI) limiting ability to give consent and/or participate fully in the study~* Currently undergoing psychotherapeutic care at the Back \& Pain Center because many of the concepts that are the focus of this study are already employed in that treatment~* Other factors that at the discretion of the investigators would adversely affect study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: NO_INTERVENTION): 75 participants will take part in three visits (baseline, 30days and 60days)
- Intervention (Type: ACTIVE_COMPARATOR): 75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SIS Evaluation of the MRI Defined Subthalamic Nucleus*

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Idiopathic PD~* Bilateral or unilateral STN-HFS for PD~* 40% improvement response to medications preoperatively~Key Exclusion Criteria:~* Missing required MR/CT imaging data

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalization with moderate to severe COVID-19, defined as fulfilling at a minimum the following clinical status category on the WHO 8-point ordinal scale: (i) score 4 \[oxygen via mask or nasal\]~* Laboratory-confirmed SARS-CoV-2 infection at index hospitalisation as determined by PCR or other validated commercial or public health assay~* Bio-ADM ≥50 pg/mL or ≥30% increase until the end of the next day (with a minimum of 35 pg/mL at all)~* DPP3 ≤30 ng/mL~* Age ≥18 years at time of screening~* Body weight ≤ 150 kg at time of screening~Exclusion Criteria:~* Life expectancy less than 3 months before COVID-19 at the discretion of the Investigator~* Invasive mechanical ventilation ≥ 72 hours at time-point of randomization~* Resuscitation \> 45 minutes~* Hypersensitivity to the active substance, to Adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies~* Uncontrolled haematological/ oncological malignancies~* Pre-existing severe chronic liver disease (i.e. Child-Pugh C) before COVID-19 hospitalization~* Absolute neutropenia \<500 per μL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adrecizumab (HAM 8101) (Type: EXPERIMENTAL): Adrecizumab (HAM 8101) on top of standard of care. Adrecizumab (HAM8101) is a humanized IgG1 monoclonal antibody (mAb). 2 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion.
- Placebo/ control substance (NaCl 0.9%) (Type: PLACEBO_COMPARATOR): 100 mL saline as single dose infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Medical Food in Adults Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is scheduled to have non-melanoma skin cancer on either the head, leg, trunk and arm removed with final wound size of 1.0 to \< 5.0 cm in diameter or with 1.0 \< 5.0 cm long axis if not circular that will be healed by secondary intent~* Participant has an acceptable state of health and nutrition~* Participant agrees not to begin taking any new medications, dietary supplements, or alternative therapies during the study period~* Participant is interested in participating in the study, willing to comply with the study protocol, and willing to consume two servings of drink mix per day according to the protocol~* Participant has voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability (HIPAA) authorization prior to any study participation~Exclusion Criteria:~* Participant has a disease or condition that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the participant with study visits/procedures~* Participant has type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus~* Participant has known immunosuppression~* Participant has platelet or coagulation disorders~* Therapy with another investigational agent within 30 days of Visit 1 that has not been approved~* Systemic infection at the time of enrollment in the study~* Currently receiving or have received recombinant human platelet-derived growth factor or similar therapies, or other bioengineered tissue therapy within the previous 4 weeks~* Participant has an allergy or intolerance to any ingredient in the study product~* Participant is taking nutritional supplement(s)/capsules/formulas for wound healing and is unwilling to discontinue therapy for the duration of the study~* Participation in another clinical study

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Product (Type: EXPERIMENTAL): Drink mix powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with biochemical progression during ADT or combination therapies including ADT who are referred for imaging evaluation (prostate specific antigen \[PSA\] level \>= 1 ng/ml that has increased on at least 2 successive occasions at least 1 weak apart)~* Patients with bone scan scheduled or performed~  * Within 30 days of the PSMA PET, without any new prostate cancer (PCa) therapy in between~ * Bone scans performed at University of California, Los Angeles (UCLA) and external institutions are eligible if Digital Imaging and Communications in Medicine (DICOM) images can be obtained, imported, and anonymized~* Patients enrolled in other clinical trials are eligible if they satisfy all other criteria of eligibility~* Patients or their legal representatives must have the ability to read, understand and provide written informed consent~Exclusion Criteria:~* Initiation of a new therapy between the PSMA PET/CT and the bone scans~* Inability to provide written informed consent~* Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (68Ga-PSMA-11 PET/CT) (Type: EXPERIMENTAL): Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically- confirmed metastatic breast adenocarcinoma~* At least one previous chemotherapy regimen for metastatic breast cancer~* Age 18-75 years~* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)~* Performance status (WHO) 0-2~* Adequate liver function(serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases), adequate renal function (serum creatinine \<1.5 times the upper normal limit) and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function~* No radiation of measurable disease (except brain metastases)~* No progressive brain metastases according to clinical or radiological criteria~* No brain metastases without prior radiation therapy~* Written informed consent~Exclusion Criteria:~* Patient unable to take oral medication~* Active infection~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* History of stroke~* Anticoagulation therapy (except of low dose aspirin \<325mg)~* Other invasive malignancy except nonmelanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Vinorelbine metronomic + bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Emergency Department admission~2. Age ≥ 18 years~3. NRS ≥ 5~4. Stable vital signs defined as systolic blood pressure ≥ 90 mmHg, heart rate between 60 and 150 per minute, respiratory rate between 8 and 26 per minute, oxygen saturation greater than or equal to 92%~Exclusion Criteria:~1. Initial management by trauma-team~2. Systolic blood pressure ≥ 180mmHg, severe untreated arrhythmia, unstable angina, recent myocardial infarction (\< 30 days), severe heart-failure (Ejection fraction \< 40 %)~3. Symptoms of untreated hyperthyroidism~4. Cirrhosis with ascites~5. Known/suspected pregnancy or breastfeeding~6. Patients for whom consent is not obtainable or psychiatric forced treatment.~7. Previously enrolled in the trial~8. Psychiatric illness prior to admission defined as prior psychosis/schizophrenia~9. Untreated diagnosed glaucoma~10. Known hypersensitivity to ketamine or to any excipient or prior use of ketamine with a negative experience (i.e. hallucinations)~11. Patient clearly influenced by drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention, low-dose ketamine (Type: EXPERIMENTAL): Two 1 ml syringes with Esketamine (5 mg/ml) will be prepared and study drug will be administered as intravenous bolus dose, 0,1 mg/kg. The study drug will be administered after an intravenous morphine dose.
- Placebo (Type: PLACEBO_COMPARATOR): Two 1 ml syringes with saline will be prepared and study drug will be administered as intravenous dose, same volume as if Esketamine. The placebo drug will be administered after an intravenous morphine dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment~* Total WBC recovery of 500 mm3 prior to IL-2 treatment~* Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment~* Active infection controlled prior to starting IL-2 treatment~* Stable systolic blood pressure \> 90mm Hg prior to starting IL-2 treatment~* O2 saturation \>90% prior to starting treatment~* Stable cardiopulmonary status prior to starting IL-2 treatment~* Serum creatinine \< or equal to 2.0 mg/dl~* Total bilirubin and AST \<3x upper limits normal~Exclusion Criteria:~* Acute Promyelocytic Leukemia~* Active thrombocytopenic bleeding~* Cardiac ejection fraction below 45%~* Pregnancy and/or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- interleukin-2 (Type: EXPERIMENTAL): interleukin-2 therapy during lymphocyte recovery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Steroids in Children Hospitalized With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent by legal guardian~* Age 2 to 18 years old~* Admission to the floor with acute asthma exacerbation.~* Received single dose of oral Dexamethasone~* Initial Pediatric Asthma Score (PAS) of 8 or higher.~Exclusion Criteria:~* Admission to PICU~* Recent steroid use (within 1 month)~* Cardiac disorder, chronic respiratory illness (BPD or CF)~* Stridor~* Bacterial Pneumonia

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
- Prednisone (Type: ACTIVE_COMPARATOR): Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Unilateral Vestibulopathy and Corticosteroid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* definite unilateral vestibulopathy~* no pathological HINTS (examination criteria in acute vestibular syndrome)~* capable of making their own decisions~Exclusion Criteria:~* tinnitus or hearing loss with same debut as vertigo~* history of bleeding peptic ulcer~* glaucoma~* pregnancy or non-acceptance to use anticonception measures during 13 days after debut~* high blood pressure \>180 systolic, 105, diastolic~* ketoacidosis with a Base Excess \>=2~* psychic disorder (not including mild depression)~* serious infection (neutropenia, tuberculosis)~* chronic otitis~* history of vertiginous disease; Ménière, Vertiginous migraine, atypical BPPV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
- Short treatment (Type: ACTIVE_COMPARATOR): Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
- Standard treatment (Type: ACTIVE_COMPARATOR): Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oxygenation Between Nasal PAP vs Nasal During Propofol-based Sedation for EUS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years of age or older~2. Patients undergoing upper endoscopic ultrasound~3. American Society of Anesthesiology (ASA) Physical Status I-III~4. BMI ≥35 kg/m2 or documented Obstructive Sleep Apnea~5. Has provided written informed consent~Exclusion Criteria:~1. Inpatient status~2. Active Congestive Heart Failure Exacerbation~3. Untreated ischemic heart disease~4. Acute exacerbation of respiratory disorders, including COPD and asthma~5. Emergent procedures~6. Pregnancy~7. Previous enrollment in this study~8. Inability to provide informed consent~9. Additional medical testing planned for the same day~10. History of allergic reaction to Propofol~11. Tracheostomy~12. Supra-glottic or sub-glottic tumor~13. Gastrointestinal tract obstruction or delayed transit (including delayed gastric emptying, gastric bezoar, achalasia, toxic megacolon).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Facial mask (Type: ACTIVE_COMPARATOR): facial mask for oxygen delivery
- SuperNO2VA (Type: EXPERIMENTAL): SuperNO2VA is CPAP device to deliver oxygen with nasal mask rather than with facial mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed primary therapy such that no disease is evident at the time of enrollment in the study~Exclusion Criteria:~* Patients unable to consent~* Without diagnosis of colorectal cancer~* Non-small cell lung cancer or squamous cell cancer of the head and neck~* Unwilling or unable to participate in the assigned follow-up program~* Having a serum glucose at time of PET/CT greater than 180mg/dl~* Stage IV disease or with evidence of disease recurrence post treatment~* Who are not a candidate for further treatment should a recurrence of disease be identified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PET/CT follow-up (Type: ACTIVE_COMPARATOR): PET/CT with history and physical exams at 3,9,18,36,60 months only
- conventional follow-up (Type: OTHER): NCCN recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues